Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program

MT Newswires Live

06/22

Traws Pharma (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.

Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.

The company said it expects a formal response from the regulator within 30 days of the resubmission.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2645022306"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645022306\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645022306?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645022306","market":"us","top_or_hot":-1,"title":"Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.</p><p>Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.</p><p>The company said it expects a formal response from the regulator within 30 days of the resubmission.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-22 20:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.</p><p>Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.</p><p>The company said it expects a formal response from the regulator within 30 days of the resubmission.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645022306","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645022306","pubTimestamp":1782131035,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Traws Pharma  said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.The company said it expects a formal response from the regulator within 30 days of the resubmission.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TRAW":"TRAWS PHARMA"},"translate_title":"Traws Pharma表示正在开发流感预防计划的最新毒理学数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAW":1},"content_text":"Traws Pharma (TRAW) said Monday it has started developing an updated toxicology data package for the planned phase 2a human influenza challenge study of tivoxavir marboxil in response to information requirements from the UK's Medicines and Healthcare Products Regulatory Agency.Traws said it expects to resubmit the updated data package to the MHRA during Q3 to enable the human challenge study to proceed and provide proof of concept data for the use of tivoxavir marboxil as an oral prophylaxis medicine.The company said it expects a formal response from the regulator within 30 days of the resubmission.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}